Asunaprevir (Standard)
Asunaprevir (Standard) is the analytical standard of Asunaprevir. This product is intended for research and analytical applications. Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM[1]. Asunaprevir inhibits SARS-CoV-2 3CLpro activity[5].
Product Specifications
CAS Number
630420-16-5
UNSPSC
12352100
Target
HCV; HCV Protease; Reference Standards; SARS-CoV
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Others
Field of Research
Infection
Smiles
ClC1=CC=C2C(C(O[C@H]3CN(C([C@@H](NC(OC(C)(C)C)=O)C(C)(C)C)=O)[C@H](C(N[C@@]4(C(NS(C5CC5)(=O)=O)=O)[C@H](C=C)C4)=O)C3)=NC=C2OC)=C1
Molecular Formula
C35H46ClN5O9S
Molecular Weight
748.29
References & Citations
[1]Pelosi LA, et al. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor BMS-790052. 
 Antimicrob Agents Chemother. 2012 Jul 30.|[2]McPhee F, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032) .
 Antimicrob Agents Chemother. 2012 Aug 6.|[3]McPhee F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
 Antimicrob Agents Chemother. 2012 Jul;56 (7) :3670-81.|[4]Pasquinelli C, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.
 Antimicrob Agents Chemother. 2012 Apr;56 (4) :1838-44.|[5]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog